Citius Oncology (CTOR) Non Operating Income (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Non Operating Income data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Non Operating Income changed N/A year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$181659.0, changed N/A from the prior year.
• Non Operating Income for Q1 2026 stood at $1.8 million, up from -$17553.0 in the prior quarter.
• Over the last five years, Non Operating Income for CTOR reached as high as $2.2 million in Q3 2023 and fell as low as -$17553.0 in Q4 2025.
• Historically, Non Operating Income has averaged $982886.6 across 4 years, with a median of $759647.0 in 2023.
• On a YoY basis, Non Operating Income climbed as much as 0.18% in 2024 and fell as far as 21.99% in 2024.
• Year by year, Non Operating Income stood at $2.2 million in 2023, then tumbled by 70.47% to $636419.0 in 2024, then plunged by 102.76% to -$17553.0 in 2025, then soared by 10199.07% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $1.8 million in Q1 2026, -$17553.0 in Q4 2025, and $636419.0 in Q2 2024.